0001209191-20-031876.txt : 20200522
0001209191-20-031876.hdr.sgml : 20200522
20200522193126
ACCESSION NUMBER: 0001209191-20-031876
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200521
FILED AS OF DATE: 20200522
DATE AS OF CHANGE: 20200522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Munshi Amit
CENTRAL INDEX KEY: 0001612551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 20907633
MAIL ADDRESS:
STREET 1: C/O EPIRUS BIOPHARMACEUTICALS, INC.
STREET 2: 699 BOYLSTON STREET, 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-21
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001612551
Munshi Amit
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2020-05-21
4
M
0
50000
14.60
A
57750
D
Common Stock
2020-05-21
4
S
0
50000
55.00
D
7750
D
Common Stock
2020-05-22
4
M
0
34800
14.60
A
42550
D
Common Stock
2020-05-22
4
S
0
5390
56.6731
D
37160
D
Common Stock
2020-05-22
4
S
0
9017
57.5205
D
28143
D
Common Stock
2020-05-22
4
S
0
13931
58.6075
D
14212
D
Common Stock
2020-05-22
4
S
0
6462
59.1174
D
7750
D
Employee Stock Option (right to buy)
14.60
2020-05-21
4
M
0
50000
0.00
D
2024-02-13
Common Stock
50000
149800
D
Employee Stock Option (right to buy)
14.60
2020-05-22
4
M
0
34800
0.00
D
2024-02-13
Common Stock
34800
115000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.19 to $56.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, and 5 to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.07 to $57.97, inclusive.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.22, inclusive.
The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2020-05-22